Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Outcomes In Patients With Acute Lymphoblastic Leukemia In First Or Second Complete Remission Receiving Ex-Vivo T-Cell Depleted Or Unmodified Allografts: Comparison Of Results At Two Institutions

Gabriela Soriano Hobbs, MD, Patrick Hilden, MS, Amir Hamdi, MD, Jenna D Goldberg, MD, Michelle Poon, MD, Celina Ledesma, B.S., Sean Devlin, PhD, Gabriela Rondon, MD, Esperanza B. Papadopoulos, MD, Ann A. Jakubowski, MD, PhD, Richard J. O'Reilly, MD, Richard E Champlin, MD, Sergio A Giralt, MD, Partow Kebriaei, MD, Miguel Angel Perales, MD

Blood (2013) 122 (21): 3370.

https://doi.org/10.1182/blood.V122.21.3370.3370

Published: 2013

Journal Articles

Reduced-Intensity Conditioning (RIC) and Allogeneic Stem Cell Transplantation (allo-SCT) For Relapsed/Refractory Hodgkin Lymphoma (HL) In The Brentuximab Vedotin Era: Favorable Overall and Progression-Free Survival (OS/PFS) With Low Transplant-Related Mortality (TRM)

Paolo Anderlini, MD, Rima M. Saliba, Ph.D., Celina Ledesma, B.S., Christina M Chancoco, Tamera Alexander, P.A., Amin Alousi, MD, Chitra M. Hosing, MD, Issa Khouri, MD, Yago Nieto, M.D., Ph.D., Uday R Popat, MD, Elizabeth J Shpall, MD, Michelle A. Fanale, M.D., Yasuhiro Oki, MD, Jorge E Romaguera, MD, Sattva Neelapu, MD, Anas Younes, M.D., Richard E Champlin, MD

Blood (2013) 122 (21): 410.

https://doi.org/10.1182/blood.V122.21.410.410

Published: 2013

Journal Articles

Gemcitabine, Fludarabine, and Melphalan (G-FM) as Reduced-Intensity Conditioning (RIC) Regimen for Allogeneic Stem Cell Transplantation (Allo-SCT) in Relapsed and Refractory Hodgkin Lymphoma (HL)

Paolo Anderlini, MD, Rima M Saliba, PhD, Celina Ledesma, B.S., Christina M Chancoco, Sandra Acholonu, Rosamar Valverde, Uday R Popat, MD, Chitra M Hosing, MD, Amin M Alousi, MD, Elizabeth J Shpall, MD, Yago Nieto, MD, PhD, Stefan O Ciurea, MD, Issa Khouri, MD, Richard Champlin, MD

Blood (2011) 118 (21): 3003.

https://doi.org/10.1182/blood.V118.21.3003.3003

Published: 2011

Journal Articles

Pre-Transplant Minimal Residual Disease Detected by Multiparameter Flow Cytometric Analysis Predicts for Disease Relapse in Adult Patients with Acute Lymphoblastic Leukemia Post Allogeneic Hematopoietic Stem Cell transplantation

Yi Zhou, MD, PhD, Jeffrey L. Jorgensen, MD, PhD, Rima M Saliba, PhD, Sa A. Wang, MD, Gabriela Rondon, MD, Celina Ledesma, B.S., Borje S Andersson, MD, PhD, Marcos J de Lima, MD, Elizabeth J Shpall, MD, Uday Popat, M.D., Stefan O Ciurea, MD, Amin M Alousi, MD, Muzaffar Qazilbash, MD, Chitra M Hosing, MD, L. Jeffrey Medeiros, MD, Richard Champlin, MD, Partow Kebriaei, MD

Blood (2011) 118 (21): 3072.

https://doi.org/10.1182/blood.V118.21.3072.3072

Published: 2011

Journal Articles

Clofarabine (Clo) and Busulfan (Bu) as a Novel Reduced Toxicity Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation (HCT) In Patients (pts) with Acute Lymphoblastic Leukemia (ALL).

Partow Kebriaei, MD, Celina Ledesma, B.S., Kirk Culotta, PharmD, Elizabeth J. Shpall, MD, Stefan O. Ciurea, MD, Amin M Alousi, MD, Marcos De Lima, MD, Uday Popat, MD, Deborah A Thomas, MD, Richard E. Champlin, MD, Borje S Andersson, MD

Blood (2010) 116 (21): 3484.

https://doi.org/10.1182/blood.V116.21.3484.3484

Published: 2010

NARROW

Outcomes In Patients With Acute Lymphoblastic Leukemia In First Or Second Complete Remission Receiving Ex-Vivo T-Cell Depleted Or Unmodified Allografts: Comparison Of Results At Two Institutions

Reduced-Intensity Conditioning (RIC) and Allogeneic Stem Cell Transplantation (allo-SCT) For Relapsed/Refractory Hodgkin Lymphoma (HL) In The Brentuximab Vedotin Era: Favorable Overall and Progression-Free Survival (OS/PFS) With Low Transplant-Related Mortality (TRM)

Gemcitabine, Fludarabine, and Melphalan (G-FM) as Reduced-Intensity Conditioning (RIC) Regimen for Allogeneic Stem Cell Transplantation (Allo-SCT) in Relapsed and Refractory Hodgkin Lymphoma (HL)

Pre-Transplant Minimal Residual Disease Detected by Multiparameter Flow Cytometric Analysis Predicts for Disease Relapse in Adult Patients with Acute Lymphoblastic Leukemia Post Allogeneic Hematopoietic Stem Cell transplantation

Clofarabine (Clo) and Busulfan (Bu) as a Novel Reduced Toxicity Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation (HCT) In Patients (pts) with Acute Lymphoblastic Leukemia (ALL).

Email alerts

ASH Publications

American Society of Hematology

Outcomes In Patients With Acute Lymphoblastic Leukemia In First Or Second Complete Remission Receiving Ex-Vivo T-Cell Depleted Or Unmodified Allografts: Comparison Of Results At Two Institutions

Reduced-Intensity Conditioning (RIC) and Allogeneic Stem Cell Transplantation (allo-SCT) For Relapsed/Refractory Hodgkin Lymphoma (HL) In The Brentuximab Vedotin Era: Favorable Overall and Progression-Free Survival (OS/PFS) With Low Transplant-Related Mortality (TRM)

Gemcitabine, Fludarabine, and Melphalan (G-FM) as Reduced-Intensity Conditioning (RIC) Regimen for Allogeneic Stem Cell Transplantation (Allo-SCT) in Relapsed and Refractory Hodgkin Lymphoma (HL)

Pre-Transplant Minimal Residual Disease Detected by Multiparameter Flow Cytometric Analysis Predicts for Disease Relapse in Adult Patients with Acute Lymphoblastic Leukemia Post Allogeneic Hematopoietic Stem Cell transplantation

Clofarabine (Clo) and Busulfan (Bu) as a Novel Reduced Toxicity Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation (HCT) In Patients (pts) with Acute Lymphoblastic Leukemia (ALL).

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only